title: Treatment with hydrochlorothiazide and alendronate in patients with stones and bone mineral density loss. Evolution of bone metabolism and calciuria with medical treatment.
abstract: OBJECTIVE
  Treatment of calcium stones is based on diet and pharmacological measures such as the use of thiazides and other drugs. The aim of this study is to assess the effect of alendronate on hydrochlorothiazide on urinary calcium and bone mineral density in patients with calcium stones.
  
  
  METHODS
  Prospective observational study involving 77 patients with relapsing calcium stones divided into 2 groups according to treatment received. Group 1: 36 patients treated with alendronate 70 mg/week; Group 2: 41 patients treated with hydrochlorothiazide 50 mg/day. All patients receive diet recommendations and fluid intake. Studied and analyzed among other variables were bone mineral density, bone turnover markers and calciuria before and after 2 years of treatment. Statistical study with SPSS 17.0, statistical significance p<0.05.
  
  
  RESULTS
  No statistically significant differences in the distribution by sex or age of the patients between groups. In group 1 statistically a significant decrease was observed in the Β-crosslaps and improvement in bone mineral density, along with decreased urinary calcium after 2 years of treatment. In Group 2 statistically significant decrease in urinary calcium and fasting calcium/creatinine was seen, along with improvement in bone mineral density after 2 years of treatment. In group 1, there is a more obvious and significant improvement in bone mineral density compared to 2 and Β-crosslaps decrease. However, in group 2 the decrease in urinary calcium and calcium/creatinine was more significant than in group 1.
  
  
  CONCLUSIONS
  Treatment with thiazide decrease calciuria and produces an improvement in bone mineral density, although not in the same range as treatment with alendronate.
authors: Instituto IBS Granada. Granada. Spain.
authors: M
authors: M
authors: Arrabal-Martín
authors: Service of Urology. Hospital de Poniente. El Ejido. Almería. Spain.
authors: S
authors: S
authors: González-Torres
authors: UGC Urología. Hospital La Inmaculada. Huércal-Overa. Almería. Spain.
authors: M C
authors: MC
authors: Cano-García
authors: UGC Análisis Clínicos. Hospital Santa Ana. Motril. Granada. Spain.
authors: A
authors: A
authors: Poyatos-Andújar
authors: UGC Urología intercentros. Complejo Hospitalario Universitario Granada. Granada. Spain.
authors: F
authors: F
authors: Abad-Menor
authors: UGC Urología. Hospital La Inmaculada. Huércal-Overa. Almería. Spain.
authors: M A
authors: MA
authors: Arrabal-Polo
mesh_terms: D019386:Alendronate / Q000627:therapeutic use*; D015519:Bone Density; D016723:Bone Remodeling; D002118:Calcium / Q000097:blood / Q000652:urine; D003404:Creatinine / Q000097:blood; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D011446:Prospective Studies; D014545:Urinary Calculi / Q000188:drug therapy*
chemical_list: D006852:Hydrochlorothiazide; D003404:Creatinine; D002118:Calcium; D019386:Alendronate